New York Blood Center

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Retrieved on: 
Tuesday, November 14, 2023
Safety, Engineering, Hope, Leukemia & Lymphoma Society, University, Stem cell, Leukemia, New York Blood Center, Investment, Patient, T-cell lymphoma, Genetic engineering, CD5, Joseph Vittoria, Cancer, Lymphoma, LLS, Pharmaceutical industry

PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.

Key Points: 
  • PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.
  • The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.
  • The additional capital will support Vittoria’s clinical development initiatives and advance its next-generation cell therapies that strengthen efficacy, improve safety, and broaden therapeutic applicability for patients with cancer and autoimmune diseases.
  • By acting on the fundamental biology of T cells, Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies.

Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Health, Clinical Trials, Medicinal chemistry, Bone cancer in cats and dogs, Surgeon, Therapy, Drug discovery, Head, Osteosarcoma, Bone, Research, Merck & Co., Factorization of polynomials, Prostaglandin, Former, Metastasis, New York Blood Center, Patient, CBO, Chronic kidney disease-mineral and bone disorder, Chief financial officer, Merck, EP4, Elective surgery, Safety, Pharmaceutical industry, Medical imaging, Dentistry

Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.

Key Points: 
  • Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.
  • The bone is a complex, dynamic tissue with unique properties that make it a formidable challenge for drug efficient penetration.
  • The company successfully dosed the first patients via subcutaneous injection in a Phase 1 study evaluating MES1022, a bone-selective EP4 receptor agonist prodrug they are developing for bone regeneration, with the first application for accelerating healing of bone fractures.
  • “MES1022 is well-positioned to be the first therapy that mimics and enhances the natural processes the body uses to stimulate bone repair and healing.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

MAK-System partners with New York Blood Centre Enterprises

Retrieved on: 
Wednesday, June 7, 2023
Patient blood management, Partnership, Service, Information technology, MD, Patient, Blood, New York Blood Center, Growth, Service-level agreement, Medical device, Pharmaceutical industry, Cryptocurrency

LONDON, June 7, 2023 /PRNewswire/ -- MAK-System , a worldwide leader in Blood Management systems, is proud to announce an extended and strategic partnership with New York Blood Center Enterprises ( NYBCe ).

Key Points: 
  • LONDON, June 7, 2023 /PRNewswire/ -- MAK-System , a worldwide leader in Blood Management systems, is proud to announce an extended and strategic partnership with New York Blood Center Enterprises ( NYBCe ).
  • The 10-year arrangement will transform how blood is managed and delivered to patients by leveraging the benefits of managed services.
  • The MAK.care platform brings a new era in the blood and biologics management industry and allows for more efficient and scalable connectivity for all stakeholders, including Blood Centers, donors, healthcare providers, and the pharmaceutical and biotech industry.
  • "We are extremely proud to have been selected by one of the largest and most prestigious blood centers.

NYBC Ventures Launches $50M Fund to Accelerate Innovations in Blood and Cellular Therapies

Retrieved on: 
Thursday, May 11, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Therapy, Transfusion medicine, Infection, General partnership, Organization, Venture, M.D, New York Blood Center, Blood, MPH, Pharmaceutical industry, Health care

NYBC Ventures , today announced the launch of its inaugural fund with a $50 million investment from New York Blood Center, Inc. (NYBC) to accelerate innovation in blood-related fields, and cellular therapies and enabling technologies.

Key Points: 
  • NYBC Ventures , today announced the launch of its inaugural fund with a $50 million investment from New York Blood Center, Inc. (NYBC) to accelerate innovation in blood-related fields, and cellular therapies and enabling technologies.
  • NYBC Ventures is an early-stage life sciences investment fund that will focus on investment in therapeutics, devices, and innovative technologies addressing the most pressing challenges in benign hematology, transfusion medicine, and infectious disease.
  • “This is the first venture fund solely dedicated to advancing innovation in blood and cell-based therapies and technologies,” said Christopher D. Hillyer, M.D., President and CEO, New York Blood Center Inc.; General Partner, NYBC Ventures.
  • NYBC Ventures employs a model of patient capital and takes a flexible approach to financing vehicles and structures.

MAK-SYSTEM ANNOUNCES STRATEGIC RELATIONSHIP WITH AWS FOR THE LAUNCH OF MAK.care

Retrieved on: 
Tuesday, April 25, 2023
New Zealand Blood Service, Patient blood management, Amazon Web Services, Service, Transfusion medicine, Health care, Privacy, Patient, Risk, Blood, CIO, AI, New York Blood Center, AWS, Service-level agreement, Safety, Pharmaceutical industry, Medical device

We are thrilled to be collaborating with AWS to bring our cutting-edge MAK.care platform to the global market," said Frank Jaubert, CEO of MAK-System.

Key Points: 
  • We are thrilled to be collaborating with AWS to bring our cutting-edge MAK.care platform to the global market," said Frank Jaubert, CEO of MAK-System.
  • "We see many opportunities from the introduction of MAK.care", added Dr Giulio Bognolo, MAK-System Chief Product Officer & Chief Medical Officer.
  • Our joint initiative with AWS will provide the reassurance of an available, secure, and reliable technology platform to support the customer's business.
  • "We are pleased to be working with MAK-System on this strategic initiative," said Jens Dommel, AWS Head of Healthcare for EMEA.

70,000 "We Are One" Volunteers Participate in the Largest Group Blood Donation in History

Retrieved on: 
Monday, December 5, 2022
Multimedia, New York Blood Center, Blood, Health, Patient, Shincheonji Church of Jesus, Volunteering, COVID-19, Blood transfusion, Pharmaceutical industry, Medical device, Online shopping

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- The youth volunteer group We Are One had the goal of donating blood to 70,000 people from August 27th to November 27th. During the campaign, a total of 73,807 people completed blood donations over a period of 85 days. A total of 100,360 people participated in the largest group blood donation ever recorded.The blood supply lately has been low for reasons such as decreased participation in blood donations amid the prolonged COVID-19 pandemic. With the goal of completing 70,000 blood donations by November to prepare for the winter season — along with the upcoming holidays when the blood supply is usually reduced — We Are One members actively donated blood.The campaign was conducted at blood banks in 17 metropolitan areas across South Korea and as planned, 70,000 blood donations were completed by November 27th.In order for a large number of people to donate blood in a short period of time, We Are One focused on coordinating individual schedules based on the needs of the blood banks. Volunteers made efforts to maintain their own health and ensure they would not be disqualified or prevented from donating blood. In order to reach the goal of achieving 70,000 blood donations before winter, about 100,000 We Are One members visited blood banks and joined the campaign.Junsu Hong, a representative of We Are One, said, "Blood donation is the only means to save the lives of patients who need blood transfusion and is a noble volunteer work. I appreciate all the members who participated in the blood donation with a clear sense of calling for the practice of sharing life. We Are One will continue to participate in blood donation to overcome the blood supply shortage and strengthen the community safety net."We Are One was launched on July 30th as a volunteer group composed of youth members from Shincheonji Church of Jesus located in Korea and overseas. Volunteers in areas such as New York have also actively donated blood in recent months, even receiving recognition from the New York Blood Center.This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

Key Points: 
  • A total of 100,360 people participated in the largest group blood donation ever recorded.
  • The blood supply lately has been low for reasons such as decreased participation in blood donations amid the prolonged COVID-19 pandemic.
  • The campaign was conducted at blood banks in 17 metropolitan areas across South Korea and as planned, 70,000 blood donations were completed by November 27th.
  • We Are One will continue to participate in blood donation to overcome the blood supply shortage and strengthen the community safety net."

Joseph Simone Says Outer-Ring Properties Will Meet New York City Life Science Expansion

Retrieved on: 
Wednesday, November 16, 2022
Metro-North Railroad, Acquisition, Industry, Hell Gate, New York Blood Center, Walking, Hell Gate Bridge, Pennsylvania Station, Laboratory, Private investigator, Tunnel

BRONX, N.Y., Nov. 16, 2022 /PRNewswire-PRWeb/ -- Outer-ring corporate office parks will help satisfy New York City's booming life-science sector's need for new lab and back-office space, said Joseph Simone of Simone Development Companies.

Key Points: 
  • BRONX, N.Y., Nov. 16, 2022 /PRNewswire-PRWeb/ -- Outer-ring corporate office parks will help satisfy New York City's booming life-science sector's need for new lab and back-office space, said Joseph Simone of Simone Development Companies.
  • "The limited amount of land in New York City and the expense of building in dense locations like Manhattan will motivate some life science companies to consider locations in the outer boroughs or the near suburbs that are connected to New York City," said Joe Simone , president of Simone Development Companies.
  • Simone Development Companies envisions a life sciences component to its Hutchinson Metro Center's expansion in the Bronx.
  • "Simone Development Companies will help meet the life science sector's need for new, state-of-the-art space that will be easily accessible from Manhattan's Penn Station," said Patricia Simone , principal and president of Simone Management Group.

New Heaven New Earth Church of Jesus Receives Recognition for Donating Blood

Retrieved on: 
Thursday, November 3, 2022
Gift of Life Marrow Registry, Blood, Guinness, New York Blood Center, Guinness World Records, View, Multimedia, Life, Medical device, Nightclub

In New York, 86 church members donated blood within a week through the New York Blood Center.

Key Points: 
  • In New York, 86 church members donated blood within a week through the New York Blood Center.
  • At the end of October, the New York branch of New Heaven New Earth Church of Jesus received a special certificate from the New York Blood Center for its donations.
  • Members of New Heaven New Earth are receiving recognition around the world for stepping up to give blood.
  • For more information about New Heaven New Earth Church of Jesus, please visit scjamericas.org.

Blood is Medicine: Raising Awareness to Inspire Action

Retrieved on: 
Friday, September 2, 2022
Statistics, Medicine, Cancer, New York Blood Center, Awareness, YouTube, Calendar, Disease, Blood, Hospital, Multimedia, Instagram, Acute lymphoblastic leukemia, Social media, World Blood Donor Day, Childhood cancer, Twitter, Bleeding, Risk, Oxygen, CLIC Sargent, Life, Patient, Medical device, Facebook

DAVENPORT, Iowa, Sept. 2, 2022 /PRNewswire/ -- ImpactLife is highlighting the critical role of blood donors in supporting pediatric patients during September's Childhood Cancer Awareness Month. Every day, more than 40 children are diagnosed with cancer in the United States and many of these patients will rely on blood transfusions as part of their treatment. ImpactLife seeks to raise awareness and inspire action with its "Blood is Medicine" campaign materials, now available to download and share from www.bloodcenter.org/childhoodcancer.

Key Points: 
  • DAVENPORT, Iowa, Sept. 2, 2022 /PRNewswire/ --ImpactLife is highlighting the critical role of blood donors in supporting pediatric patients during September's Childhood Cancer Awareness Month.
  • ImpactLife seeks to raise awareness and inspire action with its "Blood is Medicine" campaign materials, now available to download and share from www.bloodcenter.org/childhoodcancer .
  • Cancer patients receive blood transfusions to help treat symptoms of the disease as well as side effects caused by chemotherapy.
  • "The first night he was diagnosed, Hudson received red blood cell and platelet transfusions," said Jessica.